New York State Teachers Retirement System decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 141,099 shares of the company’s stock after selling 4,835 shares during the period. New York State Teachers Retirement System owned about 0.16% of IDEXX Laboratories worth $38,849,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Cornerstone Advisors Inc. raised its holdings in IDEXX Laboratories by 100.0% in the 2nd quarter. Cornerstone Advisors Inc. now owns 140 shares of the company’s stock valued at $39,000 after acquiring an additional 70 shares in the last quarter. Monetary Management Group Inc. bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $45,000. Anderson Fisher LLC bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $70,000. Northwestern Mutual Wealth Management Co. grew its stake in shares of IDEXX Laboratories by 37.8% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 361 shares of the company’s stock valued at $81,000 after purchasing an additional 99 shares during the period. Finally, Osborn Williams & Donohoe LLC bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $90,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently weighed in on IDXX shares. Guggenheim reiterated a “buy” rating and issued a $95.00 price objective (up from $90.00) on shares of VF in a research note on Thursday, May 23rd. Stifel Nicolaus lowered Viveve Medical from a “buy” rating to a “hold” rating and lowered their price objective for the company from $3.00 to $1.00 in a research note on Monday, July 22nd. Bank of America set a $300.00 price objective on IDEXX Laboratories and gave the company a “buy” rating in a research note on Friday, June 21st. Zacks Investment Research lowered Inflarx from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Finally, Canaccord Genuity reiterated a “speculative buy” rating and issued a GBX 70 ($0.91) price objective on shares of Bacanora Lithium in a research note on Monday, July 1st. Eight research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $273.86.

NASDAQ IDXX opened at $283.94 on Monday. The company has a market cap of $24.43 billion, a price-to-earnings ratio of 66.65 and a beta of 0.86. IDEXX Laboratories, Inc. has a one year low of $176.11 and a one year high of $292.17. The stock’s 50 day simple moving average is $276.70. The company has a debt-to-equity ratio of 14.81, a quick ratio of 0.74 and a current ratio of 1.01.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, topping the Zacks’ consensus estimate of $1.04 by $0.13. The business had revenue of $576.06 million for the quarter, compared to analyst estimates of $575.04 million. IDEXX Laboratories had a negative return on equity of 1,501.94% and a net margin of 17.33%. IDEXX Laboratories’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.01 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 4.82 earnings per share for the current year.

In related news, Director Rebecca M. Henderson sold 8,790 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $241.57, for a total transaction of $2,123,400.30. Following the sale, the director now directly owns 27,486 shares in the company, valued at approximately $6,639,793.02. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Giovani Twigge sold 2,600 shares of the stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $250.14, for a total value of $650,364.00. Following the sale, the insider now owns 12,595 shares in the company, valued at $3,150,513.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,721 shares of company stock worth $12,554,774. 2.70% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: Compound Interest and Why It Matters When Investing

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.